Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer

Priyanka Ray, Gauthami Nair, Arnab Ghosh, Snigdha Banerjee, Mikhail Y. Golovko, Sushanta K. Banerjee, Katie M. Reindl, Sanku Mallik, Mohiuddin Quadir

Research output: Contribution to journalArticle

Abstract

Limited effectiveness of Raf and MEK inhibitors has impelled the interest to use the inhibitors of Extra-cellular Receptor Kinase (ERK) pathway in combination with Gemcitabine (GEM) in pancreatic cancer. However, off-target abundance of ERK receptors, challenging physico-chemical properties, and dose-limiting toxicity of the inhibitor has presented critical challenges towards fabricating this combination amenable for clinical translation. Herein we report a pharmaceutical nanoformulation of GEM and an ERK inhibitor (SCH 772984) co-stabilized within a pH-sensing nanocarrier (NC, with a hydrodynamic diameter of 161 ± 5.0 nm). The NCs were modularly derived from a triblock, self-assembling copolymer, and were chemically conjugated with GEM and encapsulated with SCH772984 at a loading content of 20.2% and 18.3%, respectively. Through pH-mediated unfolding of the individual blocks of the copolymer, the NCs were able to control the release of encapsulated drugs, traffic through cellular membranes, engage target receptors, suppress proliferation of pancreatic cancer cells, and accumulate at disease sites. Collectively our studies showed the feasibility of co-delivery of a combination chemotherapy consisting of GEM and an ERK inhibitor from a NC platform, which can sense and respond to tumor microenvironment of pancreatic cancer setting.

Original languageEnglish (US)
Pages (from-to)407-420
Number of pages14
JournalJournal of Cell Communication and Signaling
Volume13
Issue number3
DOIs
StatePublished - Sep 1 2019

Fingerprint

gemcitabine
Chemotherapy
Combination Drug Therapy
Pancreatic Neoplasms
Phosphotransferases
Copolymers
Tumor Microenvironment
Mitogen-Activated Protein Kinase Kinases
Feasibility Studies
Hydrodynamics
Pharmaceutical Preparations
Chemical properties
Toxicity
Tumors
Cells
Membranes

Keywords

  • Drug delivery
  • Extracellular Receptor Kinase (ERK)
  • Nanocarrier
  • Pancreatic cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. / Ray, Priyanka; Nair, Gauthami; Ghosh, Arnab; Banerjee, Snigdha; Golovko, Mikhail Y.; Banerjee, Sushanta K.; Reindl, Katie M.; Mallik, Sanku; Quadir, Mohiuddin.

In: Journal of Cell Communication and Signaling, Vol. 13, No. 3, 01.09.2019, p. 407-420.

Research output: Contribution to journalArticle

Ray, Priyanka ; Nair, Gauthami ; Ghosh, Arnab ; Banerjee, Snigdha ; Golovko, Mikhail Y. ; Banerjee, Sushanta K. ; Reindl, Katie M. ; Mallik, Sanku ; Quadir, Mohiuddin. / Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. In: Journal of Cell Communication and Signaling. 2019 ; Vol. 13, No. 3. pp. 407-420.
@article{51d320d5cf3c4f11bf8e716d4534719f,
title = "Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer",
abstract = "Limited effectiveness of Raf and MEK inhibitors has impelled the interest to use the inhibitors of Extra-cellular Receptor Kinase (ERK) pathway in combination with Gemcitabine (GEM) in pancreatic cancer. However, off-target abundance of ERK receptors, challenging physico-chemical properties, and dose-limiting toxicity of the inhibitor has presented critical challenges towards fabricating this combination amenable for clinical translation. Herein we report a pharmaceutical nanoformulation of GEM and an ERK inhibitor (SCH 772984) co-stabilized within a pH-sensing nanocarrier (NC, with a hydrodynamic diameter of 161 ± 5.0 nm). The NCs were modularly derived from a triblock, self-assembling copolymer, and were chemically conjugated with GEM and encapsulated with SCH772984 at a loading content of 20.2{\%} and 18.3{\%}, respectively. Through pH-mediated unfolding of the individual blocks of the copolymer, the NCs were able to control the release of encapsulated drugs, traffic through cellular membranes, engage target receptors, suppress proliferation of pancreatic cancer cells, and accumulate at disease sites. Collectively our studies showed the feasibility of co-delivery of a combination chemotherapy consisting of GEM and an ERK inhibitor from a NC platform, which can sense and respond to tumor microenvironment of pancreatic cancer setting.",
keywords = "Drug delivery, Extracellular Receptor Kinase (ERK), Nanocarrier, Pancreatic cancer",
author = "Priyanka Ray and Gauthami Nair and Arnab Ghosh and Snigdha Banerjee and Golovko, {Mikhail Y.} and Banerjee, {Sushanta K.} and Reindl, {Katie M.} and Sanku Mallik and Mohiuddin Quadir",
year = "2019",
month = "9",
day = "1",
doi = "10.1007/s12079-019-00514-w",
language = "English (US)",
volume = "13",
pages = "407--420",
journal = "Journal of Cell Communication and Signaling",
issn = "1873-9601",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer

AU - Ray, Priyanka

AU - Nair, Gauthami

AU - Ghosh, Arnab

AU - Banerjee, Snigdha

AU - Golovko, Mikhail Y.

AU - Banerjee, Sushanta K.

AU - Reindl, Katie M.

AU - Mallik, Sanku

AU - Quadir, Mohiuddin

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Limited effectiveness of Raf and MEK inhibitors has impelled the interest to use the inhibitors of Extra-cellular Receptor Kinase (ERK) pathway in combination with Gemcitabine (GEM) in pancreatic cancer. However, off-target abundance of ERK receptors, challenging physico-chemical properties, and dose-limiting toxicity of the inhibitor has presented critical challenges towards fabricating this combination amenable for clinical translation. Herein we report a pharmaceutical nanoformulation of GEM and an ERK inhibitor (SCH 772984) co-stabilized within a pH-sensing nanocarrier (NC, with a hydrodynamic diameter of 161 ± 5.0 nm). The NCs were modularly derived from a triblock, self-assembling copolymer, and were chemically conjugated with GEM and encapsulated with SCH772984 at a loading content of 20.2% and 18.3%, respectively. Through pH-mediated unfolding of the individual blocks of the copolymer, the NCs were able to control the release of encapsulated drugs, traffic through cellular membranes, engage target receptors, suppress proliferation of pancreatic cancer cells, and accumulate at disease sites. Collectively our studies showed the feasibility of co-delivery of a combination chemotherapy consisting of GEM and an ERK inhibitor from a NC platform, which can sense and respond to tumor microenvironment of pancreatic cancer setting.

AB - Limited effectiveness of Raf and MEK inhibitors has impelled the interest to use the inhibitors of Extra-cellular Receptor Kinase (ERK) pathway in combination with Gemcitabine (GEM) in pancreatic cancer. However, off-target abundance of ERK receptors, challenging physico-chemical properties, and dose-limiting toxicity of the inhibitor has presented critical challenges towards fabricating this combination amenable for clinical translation. Herein we report a pharmaceutical nanoformulation of GEM and an ERK inhibitor (SCH 772984) co-stabilized within a pH-sensing nanocarrier (NC, with a hydrodynamic diameter of 161 ± 5.0 nm). The NCs were modularly derived from a triblock, self-assembling copolymer, and were chemically conjugated with GEM and encapsulated with SCH772984 at a loading content of 20.2% and 18.3%, respectively. Through pH-mediated unfolding of the individual blocks of the copolymer, the NCs were able to control the release of encapsulated drugs, traffic through cellular membranes, engage target receptors, suppress proliferation of pancreatic cancer cells, and accumulate at disease sites. Collectively our studies showed the feasibility of co-delivery of a combination chemotherapy consisting of GEM and an ERK inhibitor from a NC platform, which can sense and respond to tumor microenvironment of pancreatic cancer setting.

KW - Drug delivery

KW - Extracellular Receptor Kinase (ERK)

KW - Nanocarrier

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85072921395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072921395&partnerID=8YFLogxK

U2 - 10.1007/s12079-019-00514-w

DO - 10.1007/s12079-019-00514-w

M3 - Article

C2 - 30915617

AN - SCOPUS:85072921395

VL - 13

SP - 407

EP - 420

JO - Journal of Cell Communication and Signaling

JF - Journal of Cell Communication and Signaling

SN - 1873-9601

IS - 3

ER -